Applied Molecular Transport stock sinks after placebo bests ulcerative colitis drug - San Francisco Business Times

  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 68%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

$AMTI falls as ulcerative colitis trial fails and company seeks partner for late-stage study of same drug for chronic pouchitis

The signature drug from a Peninsula biotech company was bested in a mid-stage ulcerative colitis clinical trial by a placebo, according to top-line results, a result that at one point Friday sent the company's stock tumbling more than 60%.

More than 17% of 70 ulcerative colitis patients in the Phase II trial who received once-a-day AMT-101 had a"complete response," where all signs of the disease disappeared. The problem was that 20% of 35 patients who were given a placebo also had a complete response. "While we are disappointed with the top-line results, we are seeking to better understand the unexpectedly high placebo rate of clinical remission in this moderate-to-severe population," AMT Chief Medical Officer Dr.Kanwar added that AMT is"encouraged" by positive data of the same drug in patients with a condition known as chronic pouchitis. AMT is seeking a partner that would take AMT-101 into a late-stage study in that condition.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 78. in BR

Brasil Últimas Notícias, Brasil Manchetes